- Major pharmaceutical companies are heavily investing in R&D for multiple myeloma treatments across Europe.
- Pfizer, J&J, BMS, Sanofi, and AbbVie are leading innovation in personalized therapies and are key players in the multiple myeloma treatment market.
Johnson & Johnson Joins National Clinical Network for Multiple Myeloma Research
What happened
The International Myeloma Foundation announced the launch of the US Myeloma Network (USMN), a national clinical research network designed to accelerate the prevention and cure of multiple myeloma. Johnson & Johnson joined this initiative as the network's first industry collaborator. The USMN connects academic centers, community oncology practices, and industry partners to streamline clinical trials and expand access to new therapies.
From prnewswire.com
Why it matters
The USMN is focused on clinical trials with the potential to change clinical practice across care settings. By coordinating research across the country, the network aims to accelerate the delivery of innovative therapies and new treatment approaches to patients.
Pfizer, Johnson & Johnson, BMS, Sanofi, and AbbVie are key players in the multiple myeloma treatment market, with major pharmaceutical companies heavily investing in R&D for treatments across Europe.
From prnewswire.com
Who's involved
- Johnson & JohnsonJoined the US Myeloma Network as the first industry collaborator.
- International Myeloma FoundationLaunched the US Myeloma Network to advance scientific discovery in myeloma.
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
International Myeloma Foundation
non-profit organization in North Hollywood, California, United States
Nothing else this week.